Integrated Advisors Network LLC Reduces Position in Elevance Health, Inc. $ELV

Integrated Advisors Network LLC lowered its stake in Elevance Health, Inc. (NYSE:ELV) by 26.3% in the first quarter, HoldingsChannel reports. The institutional investor owned 3,651 shares of the company’s stock after selling 1,304 shares during the period. Integrated Advisors Network LLC’s holdings in Elevance Health were worth $1,069,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in ELV. Unison Advisors LLC raised its stake in Elevance Health by 0.4% in the 1st quarter. Unison Advisors LLC now owns 7,430 shares of the company’s stock worth $2,175,000 after acquiring an additional 32 shares during the last quarter. Greatmark Investment Partners Inc. increased its holdings in shares of Elevance Health by 5.0% in the first quarter. Greatmark Investment Partners Inc. now owns 38,622 shares of the company’s stock valued at $11,306,000 after purchasing an additional 1,845 shares during the period. Stephens Inc. AR increased its holdings in shares of Elevance Health by 3.6% in the first quarter. Stephens Inc. AR now owns 9,498 shares of the company’s stock valued at $2,781,000 after purchasing an additional 326 shares during the period. AdvisorShares Investments LLC raised its stake in shares of Elevance Health by 14.3% in the first quarter. AdvisorShares Investments LLC now owns 1,600 shares of the company’s stock worth $468,000 after purchasing an additional 200 shares during the last quarter. Finally, Howe & Rusling Inc. raised its stake in shares of Elevance Health by 23.3% in the first quarter. Howe & Rusling Inc. now owns 38,693 shares of the company’s stock worth $11,327,000 after purchasing an additional 7,319 shares during the last quarter. 89.24% of the stock is currently owned by institutional investors and hedge funds.

Elevance Health Price Performance

NYSE:ELV opened at $415.99 on Thursday. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.70. Elevance Health, Inc. has a 52 week low of $273.71 and a 52 week high of $427.19. The stock’s 50-day moving average price is $395.21 and its 200-day moving average price is $352.48. The stock has a market capitalization of $90.34 billion, a PE ratio of 17.69, a price-to-earnings-growth ratio of 2.38 and a beta of 0.67.

Elevance Health (NYSE:ELV) last released its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share for the quarter, topping analysts’ consensus estimates of $10.74 by $1.84. The company had revenue of $49.49 billion during the quarter, compared to analysts’ expectations of $48.21 billion. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.Elevance Health’s quarterly revenue was up 1.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $11.97 EPS. Elevance Health has set its FY 2026 guidance at 19.850- EPS. As a group, equities analysts expect that Elevance Health, Inc. will post 26.86 EPS for the current fiscal year.

Elevance Health Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th were paid a dividend of $1.72 per share. This represents a $6.88 annualized dividend and a dividend yield of 1.7%. The ex-dividend date of this dividend was Wednesday, June 10th. Elevance Health’s dividend payout ratio is presently 29.26%.

Analyst Upgrades and Downgrades

ELV has been the topic of a number of recent research reports. The Goldman Sachs Group upped their target price on Elevance Health from $350.00 to $370.00 and gave the company a “neutral” rating in a research report on Friday, April 24th. Mizuho lifted their price objective on shares of Elevance Health from $435.00 to $465.00 and gave the company an “outperform” rating in a research note on Monday, June 8th. JPMorgan Chase & Co. upped their price objective on shares of Elevance Health from $411.00 to $476.00 and gave the company an “overweight” rating in a report on Monday, June 8th. Weiss Ratings upgraded shares of Elevance Health from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, May 18th. Finally, Guggenheim raised their target price on shares of Elevance Health from $396.00 to $399.00 and gave the stock a “buy” rating in a report on Friday, April 24th. Fifteen analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, Elevance Health has an average rating of “Moderate Buy” and a consensus target price of $422.10.

Insider Activity

In other news, Director Robert L. Dixon, Jr. sold 151 shares of the stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $401.77, for a total transaction of $60,667.27. Following the transaction, the director owned 10,734 shares in the company, valued at $4,312,599.18. This trade represents a 1.39% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.34% of the stock is owned by company insiders.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.